More than 2,500 healthcare providers have requested protective gear for their employees via Project N95, one of the latest volunteer-based efforts to mitigate equipment shortages spurred by COVID-19.

COVID-19 has exposed one of the industry's vulnerabilities—surge capacity, prompting the search for solutions to mitigate future disasters.

An estimated 4,000 U.S. hospitals outsource their emergency departments seeking a staffing, financial and performance boost. But keeping patients in-network is getting harder.

Many private-practice physician groups have seen in-person visits drop 40% to 60%, jeopardizing their viability.

Nurses are telling their coworkers that N95 respirators are safer than the standard masks that their hospitals are offering for COVID-19 cases, resulting in reprimands from their employers.

A projected 5.4% clip of average annual healthcare spending growth—up from 4.5% in 2019—would continue to outpace inflation.

Some front-line healthcare workers have had to justify their requests for masks, use protective gear longer than manufacturers' recommendations and re-use equipment.

While the FDA is investigating whether the inexpensive, old anti-malaria drugs can tame symptoms and limit the spread of COVID-19, hospitals have responded to clinical trials in other countries that have shown promising results.

A myriad of factors will buffet hospitals as they scramble to deal with COVID-19, Moody's Investors Service analysts project as they adjust not-for-profits' outlook from stable to negative.

Parkland Health & Hospital System in Dallas administers one of Texas’ 28 local provider participation funds that generate a portion of the state’s share of Medicaid matching payments.

While hospitals benefited from the ACA’s coverage boost, they claim that a growing Medicaid reimbursement shortfall diluted those gains.

While the FDA will oversee foreign manufacturing through alternative methods, drug and device approvals will likely be delayed.

Hospitals weigh these decisions as they toe a fine line between disclosing accurate information, complying with privacy laws and not inciting fear.

The Indian government restricted the exports of ingredients used to make common antibiotics to protect its domestic supply amid the outbreak.

It is the latest scheme involving drug manufacturers that allegedly paid patient copays for their own drugs through purportedly independent charities, resulting in $624 million in related settlements last year.